Role of nuclear medicine in melanoma

European Journal of Nuclear Medicine

Volumn 25, Issue 11, 1998, Pages 1567-1574

  Hoefnagel, C A ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Isolated limb perfusion; Lymphoscintigraphy; Melanoma; Sentinel node; Tumour imaging

Indexed keywords

ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER STAGING; DIAGNOSTIC IMAGING; FOLLOW UP; HUMAN; LIMB PERFUSION; LYMPH NODE DISSECTION; MELANOCYTE; MELANOMA; REVIEW;

HUMANS; MELANOMA; NUCLEAR MEDICINE;

EID: 0031770353     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050337     Document Type: Review

References (47)

1. NIH Consensus Development Panel on Early Melanoma. Diagnosis and treatment of early melanoma. JAMA 1992; 268: 1314-1319.
2. Clark WH. A classification of malignant melanoma in man correlated with histogenesis and biological behavior. In: Hu WMAF (ed) Advances in biology of the skin. The pigmentary system. London: Pergamon; 1967: 621-647.
3. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-908.
4. Balch CM, Houghton AN, Milton GW, Sohen AS, Soong SJ, eds. Cutaneous melanoma. Philadelphia: Lippincott; 1992: 165-187.
5. Thompson JF, Hunt JA, Shannon KF, Kam PCA. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132: 903-907.
6. Bennett LR, Lago G. Cutaneous lymphoscintigraphy in malignant melanoma. Semin Nucl Med 1983; 13: 61-69.
7. Uren RF, Howman-Giles RB, Thompson JF, Hoefnagel CA. Melanoma. In: Murray IPC, Ell PJ, eds. Nuclear medicine in clinical diagnosis and treatment, 2nd edition. Edinburgh: Churchill Livingstone, 1998: 989-1001.
8. Jonk A, Kroon BBR, Mooi WJ, Hoefnagel CA. Contralateral inguinal lymph node metastasis in patients with melanoma of the lower extremities. Br J Surg 1989; 76: 1161-1162.
9. Hoefnagel CA, Jonk A. Kroon BBR: Contralateral lymph node metastasis in patients with melanoma of the lower extremity: a lymphoscintigraphic explanation. J Nucl Med 1989; 30: 912.
10. Hagler WS, Jarrett JH, Humphrey WT. The radioactive phosphorus uptake test in diagnosis of uveal melanoma. Arch Ophthalmol 1970; 83: 548-557.
11. Kirkwood JM, Myers JE, Vlock DR, Neumann R, Ariyan S, Gottschalk A, Hoffer P. Tomographic Gallium-67 citrate scnning: useful new surveillance for metastatic melanoma. Arch Int Med 1982; 97: 694-699.
12. Kagan R, Witt T, Bines S, Mesleh G, Economou S. Gallium-67 scanning for malignant melanoma. Cancer 1988; 61: 272-274.
13. 57Co-bleomycin scintigraphy in silent mediastinal metastases of malignant melanoma. Eur J Nucl Med 1985, 10: 86-87.
14. Foster N, Woo DV, Kaltovich F, Emrich J, Ljungquist C. Delineation of a transplanted malignant melanoma with indium-111-labelled porphyrin. J Nucl Med 1985; 26: 756-760.
15. Lorberboym M, Mandell LR, Mosesson RE, Germano I, Lou W, DaCosta M, Linzer DG, Machac J. The role of thallium-201 uptake and retention in intracranial tumors after radiotherapy. J Nucl Med 1997; 38: 223-226.
16. Alonso O, Martinez M, Lago G, et al. Scintigraphic detection of invasive cutaneous malignant melanoma with Tc-99m MIBI. Clin Nucl Med 1996; 21: 557-559.
17. Larson SM, Brown JP, Wright PW, Carrasquillo JA, Hellstrom I, Hellstrom KE. Imaging of melanoma with I-131 labelled monoclonal antibodies. J Nucl Med 1983; 24: 123-129.
18. Murray JL, Rosenblum MG, Lamki K, et al. Clinical parameters related to optimal tumor localization of indium-111-labelled mouse antimelanoma monoclonal antibody ZME-018. J Nucl Med 1987; 28: 25-33.
19. Eary JF, Schroff RW, Abrams PG, et al. Successful imaging of malignant melanoma with Technetium-99m-labelled monoclonal antibodies. J Nucl Med 1989; 30: 25-32.
20. 99mTc-labelled monoclonal antibody fragments. Eur J Nucl Med 1990; 16: 317-323.
21. 99mTc-labelled cutaneous melanoma antibody fragments. Br J Ophthalmol 1987; 71: 651-658.
22. 111indium-labelled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994; 73: 1731-1737.
23. 99mTc-interleukin-2. Eur J Nucl Med 1995; 22: 780.
24. 99mtechnetium-J002X acylated polygalactoside in melanoma recurrence. Eur J Dermatol 1995; 5: 600-606.
25. 131I-labelled quinoline and tyrosine derivatives. Eur J Nucl Med 1981; 6: 227-233.
26. 123I]-iodoquinoline. J Nucl Med 1984; 25: 800-804.
27. Coderre JA, Packer S, Fairchild RG, et al. Iodothiouracil as a melanoma localizing agent. J Nucl Med 1986; 27: 1157-1164.
28. Cohen MB, Saxton RE, Lake RR, et al. Detection of malignant melanoma with iodine-123 iodoamphetamine. J Nucl Med 1988; 29: 1200-1206.
29. 131I metaiodobenzylguanidine and malignant melanoma. Ned Tijdschr Geneeskd 1990; 134: 2054-2057.
30. Hoefnagel CA. MIBG and somatostatin in oncology: role in the management of neural crest tumors. Eur J Nucl Med 1994; 21: 561-581.
31. Michelot JM, Moreau MF, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, Bussiere F, Souteyrand PA, Mauclaire LP, Chossat FM. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J Nucl Med 1993; 34: 1260-1266.
32. Hoefnagel CA, Rankin EM, Valdés Olmos RA, Israels SP, Pavel S, Janssen AGM. Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotide. Eur J Nucl Med 1994; 21: 587-588.
33. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674.
34. Lindholm P, Leskinen S. Någren K, Lehikoinen P, Ruotsalainen U, Teräs M, Joensuu H. Carbon-11-methionine PET imaging of malignant melanoma. J Nucl Med 1995; 36: 1806-1810.
35. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995; 36: 1825-1835.
36. Hoefnagel CA, Valdés Olmos RA, Rankin EM, Israels SP. Melanoma detection using Indium-111 pentetreotide. Eur J Nucl Med 1995; 22: 753.
37. Virgolini I, Kurtaran A, Raderer M, et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 1995; 36: 1732-1739.
38. Wraight EP, Bard DR, Maughan TS, Knight CG, Page-Thomas DP. The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br J Radiol 1992; 65: 112-118.
39. Morion DL, Wen D, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
40. Rutgers EJT, Muller SH, Hoefnagel CA. The use of intraoperative probes in surgical oncology. In: Murray IPC, Ell PJ, eds. Nuclear medicine in clinical diagnosis and treatment, 2nd edn. Edinburgh: Churchill Livingstone, 1998:1025-1036.
41. Kapteijn BAE, Nieweg OE, Muller SH, Liem IH, Hoefnagel CA, Rutgers EJT, Kroon BBR. Validation of gamma probe detection of the sentinel node in melanoma. J Nucl Med 1997; 38: 362-366.
42. Kapleijn BAE, Nieweg OE, Valdés Olmos RA, Liem IH, Panday RK, Hoefnagel CA, Kroon BBR. Reproducibility of lymphoscintigraphy for lymphatic mapping in patients with cutaneous melanoma. J Nucl Med 1996; 37: 972-975.
43. Uren RF, Howman-Giles RB, Shaw HM, Thompson JF, McCarthy WH. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med 1993; 1998; 34: 1435-1440.
44. Jansen L, Nieweg OE, Kapteijn BAE, Valdés Olmos RA, Hoefnagel CA, Kroon BBR. Accuracy of lymphoscintigraphy in indicating the number of sentinel lymph nodes in patients with melanoma. Proc World Fed of Surg Oncol Soc and Soc of Surg Oncol Joint Meeting, San Diego.
45. Morton DL, Wen D, Foshag LJ, Essner R, Cochran A. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol 1993; 11: 1751-1756.
46. Larson SM, Carrasquillo JA, McGuffin RW, et al. Use of I-131 labelled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience. Radiology 1985; 155: 487-492.
47. Divgi CR, Larson SM. Radiolabelled monoclonal antibodies in the diagnosis and treatment of malignant melanoma. Semin Nucl Med 1989; 19: 252-261.